Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 7:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Teriflunomide Clear all
Completed Phase 3 Interventional Results available

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)

NCT04410978
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Tolebrutinib, Teriflunomide, Placebo to match Tolebrutinib, Placebo to match Teriflunomide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
974 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
23
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 18, 2026, 7:06 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis

NCT02201108
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Teriflunomide, Placebo
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
10 Years to 17 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
4
States / cities
Cullman, Alabama • Tampa, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 18, 2026, 7:06 AM EDT
Completed Phase 2 Interventional Results available

Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis

NCT00811395
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Teriflunomide, Placebo (for teriflunomide), Interferon-β [IFN-β], Glatiramer Acetate [GA]
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 31, 2012 · Synced Oct 18, 2026, 7:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

An Observational Study on Teriflunomide-exposed Pregnancies

NCT03198351
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Teriflunomide (HMR1726)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
16 Years and older · Female only
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Oct 18, 2026, 7:06 AM EDT
Completed Phase 3 Interventional Results available

Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis

NCT02425644
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ponesimod, teriflunomide
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
10
States / cities
Carlsbad, California • Pomona, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 18, 2026, 7:06 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Rapid Elimination Procedure of Teriflunomide With Colestipol Hydrochloride

NCT02263547
View directory record Official record
Conditions
Teriflunomide Elimination, Healthy Volunteers
Interventions
teriflunomide, Colestipol
Drug
Lead sponsor
Derrick Scott Robertson
Other
Eligibility
18 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 18, 2026, 7:06 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)

NCT05156281
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Remibrutinib, Teriflunomide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,007 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
50
States / cities
Phoenix, Arizona • Hanford, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 18, 2026, 7:06 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

NCT06372145
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Interventions
Tolebrutinib, Placebo, Teriflunomide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
52
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 18, 2026, 7:06 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis

NCT00475865
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Teriflunomide, Placebo (for teriflunomide), Glatiramer Acetate (GA)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Oct 18, 2026, 7:06 AM EDT
Completed No phase listed Observational

Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)

NCT02776072
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
2,978 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
38
States / cities
Homewood, Alabama • Gilbert, Arizona • Hanford, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 18, 2026, 7:06 AM EDT
Recruiting Phase 1Phase 2 Interventional

Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis

NCT04799288
View directory record Official record
Conditions
HAM/TSP
Interventions
Teriflunomide
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 120 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 18, 2026, 7:06 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

NCT04586010
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Fenebrutinib, Teriflunomide, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
32
States / cities
Birmingham, Alabama • Homewood, Alabama • Phoenix, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 18, 2026, 7:06 AM EDT
Terminated Phase 3 Interventional Results available

Study of Evobrutinib in Participants With RMS (evolutionRMS 1)

NCT04338022
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Teriflunomide, Evobrutinib
Drug
Lead sponsor
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
51
States / cities
Mobile, Alabama • Phoenix, Arizona • Long Beach, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 18, 2026, 7:06 AM EDT
Completed No phase listed Observational

Teriflunomide Tecfidera LMCE

NCT03526224
View directory record Official record
Conditions
Tecfidera, Teriflunomide
Interventions
Dimethyl Fumarate, Teriflunomide
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 18, 2026, 7:06 AM EDT
Completed Phase 3 Interventional Results available

Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis

NCT00803049
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Teriflunomide (HMR1726)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
4
States / cities
Maitland, Florida • Fort Wayne, Indiana • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 18, 2026, 7:06 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis

NCT00489489
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Teriflunomide, Placebo (for Teriflunomide), Interferon-β
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Oct 18, 2026, 7:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mechanistic Studies of Teriflunomide in RRMS

NCT03464448
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Teriflunomide
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Oct 18, 2026, 7:06 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis

NCT02792218
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Ofatumumab subcutaneous injection, Teriflunomide-matching placebo capsules, Teriflunomide capsule, Matching placebo of ofatumumab subcutaneous injections
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
930 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
56
States / cities
Phoenix, Arizona • Berkeley, California • Fullerton, California + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2021 · Synced Oct 18, 2026, 7:06 AM EDT
Completed Phase 3 Interventional Results available

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)

NCT04410991
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Tolebrutinib, Teriflunomide HMR1726, Placebo to match Tolebrutinib, Placebo to match Teriflunomide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
43
States / cities
Cullman, Alabama • Phoenix, Arizona • Arcadia, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 18, 2026, 7:06 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

NCT01252355
View directory record Official record
Conditions
Multiple Sclerosis Relapse
Interventions
Teriflunomide, Placebo (for teriflunomide), Interferon-beta (IFN-beta)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
32
States / cities
Cullman, Alabama • Cordova, Alaska • Phoenix, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 18, 2026, 7:06 AM EDT
Terminated Phase 3 Interventional Results available

Study of Evobrutinib in Participants With RMS (evolutionRMS 2)

NCT04338061
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Teriflunomide, Evobrutinib
Drug
Lead sponsor
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
38
States / cities
Cullman, Alabama • Scottsdale, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 18, 2026, 7:06 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

NCT05147220
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Remibrutinib, Teriflunomide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
52
States / cities
Phoenix, Arizona • Tucson, Arizona • Fort Smith, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 18, 2026, 7:06 AM EDT
Completed Phase 3 Interventional Results available

Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis

NCT00134563
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Teriflunomide, Placebo (for teriflunomide)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,088 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Oct 18, 2026, 7:06 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)

NCT03277248
View directory record Official record
Conditions
Relapsing Multiple Sclerosis (RMS)
Interventions
Ublituximab, Teriflunomide, Oral Placebo, IV Placebo
Biological · Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
13
States / cities
Phoenix, Arizona • Aurora, Colorado • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Oct 18, 2026, 7:06 AM EDT